Compare Enveric Biosciences Inc (ENVB) vs PepsiCo, Inc. (PEP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs PepsiCo, Inc. — how do they compare? Enveric Biosciences Inc trades at $1.39 (market cap $5.32M), while PepsiCo, Inc. trades at $138.49 (market cap $184.81B). The key difference: PepsiCo, Inc. is far larger — about 34738.7× Enveric Biosciences Inc's market cap, and PepsiCo, Inc. pays a 4.37% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENVB | PEP | |
|---|---|---|
Market Cap | $5.32M | $184.81B |
Sector | Health | Consumer Staples |
52-Week High | $17.40 | $170.44 |
52-Week Low | $1.28 | $135.35 |
Enterprise Value | $408.82K | $227.30B |
Dividend Yield | — | 4.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.41, up 6.82% in the last session. The stock shows a bearish technical trend with moving averages signaling sell, but oscillators are neutral. Financially, the company reported a net loss of $8.77M for 2025, with negative ROE and ROA, though it consistently beat EPS expectations. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003.
Outlook is speculative with high risk due to negative profitability and cash burn, offset by strong analyst buy ratings (75%) and positive clinical updates. Key risks include funding needs and drug development hurdles, while catalysts hinge on regulatory milestones and partnership news.
PepsiCo (PEP) trades at $138.27, up 2.08% on the day, with technical indicators showing bearish momentum despite recent earnings beats. The company reported Q2 2026 EPS of $2.20, beating expectations of $2.19, continuing a trend of positive earnings surprises. Fundamentals show strong profitability with a 10.78% net margin and 51.59% ROE, though revenue growth remains modest at 2.2% year-over-year. Recent news highlights price cuts on snacks following consumer resistance to high prices, while institutional investors continue adjusting positions ahead of Q3 earnings.
PEP presents a mixed investment case with strong profitability metrics and consistent dividend payments offset by modest growth and pricing challenges. The consensus price target of $159.27 suggests 15% upside potential, supported by 33% analyst buy ratings. Key risks include consumer price sensitivity, North American market recovery uncertainty, and elevated debt levels at 45.85% of assets. The upcoming Q3 earnings report on April 17 will be critical for confirming the turnaround narrative.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About PepsiCo, Inc.
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →
